MedTrace Logo

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

NCT06482086 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2024-12-05

No results posted yet for this study

Summary

The current study aims to explore the potential advantages of anti-cancer therapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced thyroid cancer who have undergone conventional therapy in the past or unresectable patients .

Conditions

  • Locally Advanced Thyroid Gland Carcinoma

Interventions

DRUG

Anlotinib

8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.

DRUG

Lenvatinib

8/12 mg qd, po.

DRUG

Sorafenib

0.4 g bid, po.

DRUG

Donafenib

0.3 g bid, po.

DRUG

Everolimus

10 mg qd, po.

DRUG

Apatinib

500 mg qd, po.

DRUG

Dabrafenib + Trametinib

Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.

DRUG

Cabozantinib

Cabozantinib 60mg qd, po.

DRUG

Vandetanib

Vandetanib 300mg qd, po.

DRUG

Entrectinib

Entrectinib 600mg qd，po.

DRUG

Pralsetinib

400mg qd, po.

DRUG

Larotrectinib

100mg qd，po

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Zhihui Li, Professor · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2024-12-01
Completion
2025-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06482086 on ClinicalTrials.gov